Compare Amphastar Pharmaceuticals Inc (AMPH) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs D R Horton Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.38 (market cap $826.08M), while D R Horton Inc trades at $150.25 (market cap $42.98B). The key difference: D R Horton Inc is far larger — about 52× Amphastar Pharmaceuticals Inc's market cap, and D R Horton Inc pays a 1.19% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | DHI | |
|---|---|---|
Market Cap | $826.08M | $42.98B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $184.04 |
52-Week Low | $16.87 | $129.82 |
Enterprise Value | $1.22B | $47.70B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
D.R. Horton (DHI) trades at $151.58, up 1.36% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with declining revenue ($34.25B in 2025) and net income margins (9.51%), though valuation metrics remain reasonable (P/E 14.23). Analyst consensus leans neutral with a $163.13 price target, while cash flow trends show volatility with a $1.51B net outflow in 2025.
The housing market headwinds and cyclical nature of homebuilding present near-term risks, but DHI's scale and operational efficiency offer stability. With the stock trading below consensus targets and showing technical support at $145, value-oriented investors may find opportunity amid sector challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
